ZPHC Tirzepatide (AQ Pen) 30 mg
ALSO KNOWN AS
- Tirzepatide Pen
- Dual GLP-1/GIP Agonist
- GIP/GLP-1 Fat Loss Pen
DESCRIPTION
ZPHC Tirzepatide (AQ Pen) 30 mg is a fully dissolved, pre-filled aqueous solution containing a dual GLP-1 and GIP receptor agonist. This powerful incretin combination enhances satiety, slows gastric emptying, and improves glucose metabolism, resulting in rapid fat-loss and improved metabolic function. With no mixing required, the precision dial-a-dose pen delivers accurate micro-doses on demand—ideal for ongoing research and lifestyle integration.
DOSAGE & ADMINISTRATION
- Total Concentration: 30 mg per pen
• Delivery Format: 60 clicks × 0.5 mg per click
• Suggested Research Titration:
– Start: 0.5 mg weekly
– Increase by 0.5 mg every 4 weeks
– Maximum: 5 mg/week (10 clicks), as tolerated
• Administration: Subcutaneous injection using micro-precision dial
• Transparent volume window and tamper-evident seal with scratch-code authentication
CYCLE USE
Utilized in clinical and research contexts for long-term weight reduction, appetite control, and metabolic reprogramming. Commonly stacked with lifestyle interventions or other peptide therapies in obesity and insulin resistance protocols.
PACKAGE CONTENTS
1 pre-filled 30 mg aqueous pen (60 × 0.5 mg clicks)
STORAGE INSTRUCTIONS
• Refrigerate at 2–8°C after opening
• Stable for 30 days at 2–8°C
• Do not freeze
• Protect from light
